Literature DB >> 25588456

L-dopa does not add to the success of high-intensity language training in aphasia.

Caterina Breitenstein1, Catharina Korsukewitz1, Annette Baumgärtner2, Agnes Flöel3, Pienie Zwitserlood4, Christian Dobel5, Stefan Knecht6.   

Abstract

PURPOSE: L-dopa has been shown to improve outcome of moderate-intensity language training after stroke in acute aphasia. Given the critical role of training intensity we probed the effect of l-dopa in combination with high-intensity language training in chronic post-stroke aphasia.
METHODS: In this prospective, randomized, placebo-controlled, double-blind study, aphasia patients (>1 year post stroke) were administered 100/25 mg of l-dopa/carbidopa or placebo daily prior to four hours of language training for two weeks. Conditions were crossed-over after a wash-out period of 4 weeks.
RESULTS: An a-priori planned interim analysis (n = 10) showed that naming performance and verbal communication improved significantly and persistently for at least 6 months in every patient, but l-dopa had no incremental effect to intensive training.
CONCLUSION: High-intensity language training in chronic aphasia may take learning to a ceiling that precludes additive benefits from l-dopa. Effects of l-dopa on post-stroke recovery during less intense treatment in chronic aphasia remain to be evaluated.

Entities:  

Keywords:  Stroke; aphasia; intensive training; l-dopa; rehabilitation

Mesh:

Substances:

Year:  2015        PMID: 25588456     DOI: 10.3233/RNN-140435

Source DB:  PubMed          Journal:  Restor Neurol Neurosci        ISSN: 0922-6028            Impact factor:   2.406


  12 in total

Review 1.  [Aphasia: evidence-based therapy approaches].

Authors:  R Darkow; A Flöel
Journal:  Nervenarzt       Date:  2016-10       Impact factor: 1.214

Review 2.  [New aspects of neurorehabilitation: motor and language].

Authors:  J Liepert; C Breitenstein
Journal:  Nervenarzt       Date:  2016-12       Impact factor: 1.214

Review 3.  Pharmacotherapy to Enhance Cognitive and Motor Recovery Following Stroke.

Authors:  Xabier Beristain; Esteban Golombievski
Journal:  Drugs Aging       Date:  2015-10       Impact factor: 3.923

Review 4.  Advances and Innovations in Aphasia Treatment Trials.

Authors:  Shauna Berube; Argye E Hillis
Journal:  Stroke       Date:  2019-09-12       Impact factor: 7.914

5.  When two are better than one: Bilateral mesial temporal lobe contributions associated with better vocabulary skills in children and adolescents.

Authors:  Lisa Bartha-Doering; Astrid Novak; Kathrin Kollndorfer; Gregor Kasprian; Anna-Lisa Schuler; Madison M Berl; Florian Ph S Fischmeister; William D Gaillard; Johanna Alexopoulos; Daniela Prayer; Rainer Seidl
Journal:  Brain Lang       Date:  2018-06-15       Impact factor: 2.381

Review 6.  Treatment of post-stroke aphasia: A narrative review for stroke neurologists.

Authors:  Emilia Vitti; Argye E Hillis
Journal:  Int J Stroke       Date:  2021-06-06       Impact factor: 5.266

Review 7.  Current Approaches to the Treatment of Post-Stroke Aphasia.

Authors:  Julius Fridriksson; Argye Elizabeth Hillis
Journal:  J Stroke       Date:  2021-05-31       Impact factor: 6.967

8.  Efficacy of intensive aphasia therapy in patients with chronic stroke: a randomised controlled trial.

Authors:  Benjamin Stahl; Bettina Mohr; Verena Büscher; Felix R Dreyer; Guglielmo Lucchese; Friedemann Pulvermüller
Journal:  J Neurol Neurosurg Psychiatry       Date:  2017-12-22       Impact factor: 10.154

9.  A Review of Biological Interventions in Chronic Aphasia.

Authors:  E Susan Duncan; Aswathy Anakkathil Pradeep; Steven L Small
Journal:  Ann Indian Acad Neurol       Date:  2020-09-25       Impact factor: 1.383

10.  Intrinsically regulated learning is modulated by synaptic dopamine signaling.

Authors:  Pablo Ripollés; Laura Ferreri; Marta Valle; Jordi Riba; Antoni Rodriguez-Fornells; Ernest Mas-Herrero; Helena Alicart; Alba Gómez-Andrés; Josep Marco-Pallares; Rosa Maria Antonijoan; Toemme Noesselt
Journal:  Elife       Date:  2018-08-30       Impact factor: 8.140

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.